REPLIGEN CORP (NASDAQ: RGEN)





$3.40 0.05 (1.49%)
Real-time 12:00:00 AM ET
Turn On
KEY STATS
52-Week High Price
5.85
52-Week Low Price
3.35
Avg Volume (3 Mo.)
0.00 M
Market Cap
0.10 B
P/E Ratio (TTM)
29.3
Diluted EPS (TTM)
-0.18
Shares
30.76 M
Dividend Rate ($) / (%)
0.00/0.00
100%
0%
You need to upgrade your Flash Player to view the graph.
View by Date Range:
12 Mo. Price Change : -22% - RGEN has underperformed the S&P 500 by 48%
SIMILAR COMPANIES
NameCurrent Price - Today's ChangeMarket Cap
IMMUNOSYN CORP (IMYN) $0.40 -  $0.00(0.00%)0.10 B
INSMED INC (INSM) $0.81 -  $0.00(0.62%)0.11 B
NEUROCRINE BIOSCIENCES (NBIX) $2.37 -  $0.01(0.42%)0.09 B
TRANSCEPT PHARMACEUTICAL (TSPT) $7.74 -  $0.03(0.39%)0.10 B
TIANYIN PHARMA CO INC (TPI) $3.68 -  $0.31(7.77%)0.10 B
MYRIAD PHARMACEUTICALS (MYRX) $4.24 -  $0.04(0.95%)0.11 B
ONCOGENEX PHARMA INC (OGXI) $17.03 -  $0.76(4.70%)0.09 B
SCHIFF NUTRITION INTL (WNI) $7.81 -  $0.17(2.23%)0.10 B
EPICEPT CORP. (EPCTD) $2.06 -  $0.09(4.19%)0.10 B
CHELSEA THERAPEUTICS INT (CHTP) $2.53 -  $0.19(6.99%)0.09 B
STOCK ANALYSIS
There are currently no Stock Analysis.
RGEN RELATED HEADLINES
arrow
Great Biotech Ideas
<ul> <li>Rodman &amp; Renshaw Annual Global Investment Conference</li> <li>Oxigene discuss Zybrestat which is in Phase III</li> <li>GTX discuss Fareston and Toremifene</li> <ul>

Wall Street Media 11/11/2008
arrow
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model
Study Published in the Proceedings of the National Academy of Sciences

Forbes.com 9/16/2008
Stock Simulator- Free Account
Chart Advisor- Free Report
Sponsored Links
COLOSIM2